A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients

Molecular targeted therapy has shown potential in hepatocellular carcinoma (HCC) patients, and immunotherapy applications are developing rapidly. However, clinical guidance for making individualized therapy decisions for HCC patients remains lacking. MDH (Medication Decision in HCC) gene signatures...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jingsheng, Liu, Zijian, Wu, Zhenru, Yan, Lvnan, Yang, Jiayin, Shi, Yujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585274/
https://www.ncbi.nlm.nih.gov/pubmed/36275751
http://dx.doi.org/10.3389/fimmu.2022.990571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585274/
https://www.ncbi.nlm.nih.gov/pubmed/36275751
http://dx.doi.org/10.3389/fimmu.2022.990571

Ejemplares similares